Douglas Swirsky

Mr. Douglas J.
Swirsky, CFA MBA, is a Chief Financial & Accounting Officer at Barinthus Biotherapeutics Plc and an Independent Chairman at Cellectar Biosciences, Inc. Mr. Swirsky was previously employed as a Chief Financial & Accounting Officer by MaxCyte, Inc., a Chairman by NeuroBo Pharmaceuticals, Inc., a Chief Financial Officer & Director by AavantiBio, Inc., a President, CEO, CFO, Secretary & Director by Rexahn Pharmaceuticals, Inc., an Independent Non-Executive Director by Pernix Therapeutics Holdings, Inc., a Chairman by Fibrocell Science, Inc., a Chairman by Castle Creek Biosciences, Inc., an Independent Director by PolyMedix, Inc., a President, CEO, Secretary & Director by GenVec, Inc., a Managing Director by Stifel, Nicolaus & Co., Inc., and a MD & Head-Life Sciences Investment Banking by Legg Mason, Inc. He received his undergraduate degree from Boston University and an MBA from Kellogg School of Management.